Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Methodist Medical Center, Midwest Urological Group Target Prostate Cancer with TomoTherapy® System

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

DataOne and InterSystems Lay the Digital...

Connecting hospitals and insurers through an integrated data bridge...

InterSystems Honored with Four 2026 Best...

Recognized for excellence in Acute Care EHR and Shared...

InterSystems Payer Connector debuts on the...

New solution establishes a governed integration engine to accelerate...

TomoTherapy Incorporated announced that a new TomoTherapy® radiation therapy system has been installed in Peoria, Ill., at a facility jointly developed by Methodist Medical Center and Midwest Urological Group. The Methodist Radiation Oncology Center and Prostate Cancer Treatment Center began installation of the TomoTherapy system in mid-July 2009, and treated its first prostate cancer patient only four weeks later. The center is currently treating approximately 25 patients a day on the TomoTherapy system, which integrates true CT-based image guidance for increased treatment accuracy and helical radiation delivery for enhanced tumor targeting.

Methodist Medical Center installed Peoria’s first TomoTherapy treatment system in January 2008. Roby Lal, M.D., radiation oncologist at Methodist Radiation Oncology Center and Prostate Cancer Treatment Center, said the addition of a second TomoTherapy location enables greater access to this groundbreaking treatment. “Since Methodist Medical Center first opened the in-house TomoTherapy unit last year, we’re seeing significant success with our patients,” said Dr. Lal. “Fewer side effects allow us to escalate the treatment dosage and have better patient outcomes.”

Although the new TomoTherapy system may eventually be used to treat other cancers at this site, it will primarily be used to treat prostate cancer. According to Sarat Sabharwal, M.D., a urologist and medical director of the Methodist Radiation Oncology Center and Prostate Cancer Treatment Center, TomoTherapy technology is ideal for this use.

“The prostate moves daily as surrounding structures like the rectum and bladder change shape,” said Dr. Sabharwal. “The TomoTherapy system allows us to capture a CT image of internal anatomy immediately before each treatment and use this scan to guide the dose appropriately. Then, using the same equipment, we can deliver a highly precise form of radiation from all angles around the patient, as opposed to just a few angles as older technologies allow.”

Since the first patient treatment was delivered on a TomoTherapy system in Knoxville, Tenn., in July 2003, more than 3 million treatment sessions—targeting cancers throughout the body—have been completed on TomoTherapy systems in hospitals and cancer centers around the world.

“The TomoTherapy system is changing the way cancer is treated,” said Fred Robertson, M.D., CEO of TomoTherapy. “Our unique platform helps ensure that tumors can be eradicated while damage to nearby organs and other healthy tissue is minimized. We are pleased to partner with Methodist Medical Center and Midwest Urological Group to expand access to this advanced treatment option for patients throughout the region.”

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO.

Investor Contact:
Thomas E. Powell
Chief Financial Officer
608.824.2800
tpowell@tomotherapy.com

Media Contact:
Kevin O’Malley Manager
Corporate Communications
608.824.2800
komalley@tomotherapy.com

MEDICAL FAIR ASIA 2026

Latest stories

Related stories

DataOne and InterSystems Lay the Digital Foundation for AI-Ready Health Insurance in Thailand

Connecting hospitals and insurers through an integrated data bridge...

InterSystems Honored with Four 2026 Best in KLAS Awards

Recognized for excellence in Acute Care EHR and Shared...

InterSystems Payer Connector debuts on the Epic Showroom

New solution establishes a governed integration engine to accelerate...

InterSystems Appoints Don Woodlock as President

Boston, MA – January 6, 2026 – InterSystems, a creative...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »